Resveratrol, a polyphenolic compound with antitumor, anti-inflammatory, antioxidant, and anti-angiogenic properties [42], was recently tested in a human clinical trial to reduce VEGF and TNF-α expression in postoperative eutopic endometrium of patients with endometriosis (stage III-IV), and thus, antiangiogenic therapy may be a successful approach for the treatment of endometriosis [43]. Here, TNF is linked to endometriosis.